MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Alder Biopharmaceuticals Company Profile (NASDAQ:ALDR)

Consensus Ratings for Alder Biopharmaceuticals (NASDAQ:ALDR) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $40.50 (21.74% downside)

Analysts' Ratings History for Alder Biopharmaceuticals (NASDAQ:ALDR)
Show:
DateFirmActionRatingPrice TargetActions
6/25/2015Credit SuisseReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/24/2015Credit SuisseInitiated CoverageOutperform$50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2015Credit SuisseReiterated RatingOutperform$36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/5/2015Leerink SwannBoost Price TargetOutperform$24.00 -> $31.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/17/2014Credit SuisseBoost Price TargetOutperform$19.00 -> $34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/2/2014Leerink SwannLower Price Target$26.00 -> $24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/11/2014Sanford C. BernsteinInitiated CoverageOutperform$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2014Credit SuisseInitiated CoverageOutperform$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2014Wells Fargo & Co.Initiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2014Leerink SwannInitiated CoverageOutperform$26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/5/2013 forward)